Patient-Specific Signaling and Functional Phenotyping of hiPSC-CMs in Dilated Cardiomyopathy

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Npj Biomedical Innovations  https://doi.org/10.1038/s44385-026-00111-8
Giada Castagnola et al.

Points

McGill University researchers developed an innovative heart in a dish experimental pipeline utilizing human induced pluripotent stem cell derived cardiomyocytes to study dilated cardiomyopathy at single cell resolution.
The pilot investigation analyzed blood samples from two healthy volunteers and two patients with dilated cardiomyopathy to generate validated cell lines and assess individual molecular signaling signatures.
Investigators measured cellular responses to disease relevant G protein coupled receptor targeting ligands using advanced nuclear and cytosolic biosensors alongside functional metrics including calcium handling and contractility.
Notably, cardiomyocytes derived from the female patient exhibited a distinct hormonal response that was entirely absent in male patient samples and healthy control volunteers during testing.
Authors concluded that this high resolution single cell platform successfully identifies patient specific disease phenotypes and establishes a vital foundation for developing personalized heart failure treatments.

Summary

This pilot study evaluated patient-specific molecular signaling and functional signatures in non-ischaemic dilated cardiomyopathy (DCM) using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Published in npj Biomedical Innovations by McGill University researchers led by senior author Terry Hébert, the investigation addressed the high mortality of DCM—where approximately 50% of patients die within five years of diagnosis—and the limitations of standardized, one-size-fits-all treatment regimens that yield highly variable clinical responses. Given that incomplete molecular knowledge hinders therapeutic discovery, the research sought to establish a high-resolution experimental pipeline to uncover individual pathobiological mechanisms.

The pilot study utilized blood samples collected from two healthy volunteers and two patients with dilated cardiomyopathy, generating and validated hiPSC lines that were subsequently differentiated into functional cardiomyocytes. Single-cell level cellular signaling was assessed after treatment with disease-relevant G protein-coupled receptor (GPCR)-targeting ligands using nuclear and cytosolic PKA and ERK biosensors, coupled with advanced microscopy to evaluate calcium handling, contractility, and electrophysiology. Notably, cardiomyocytes derived from the female patient demonstrated a unique hormonal signaling response not observed in the male patient or healthy controls, highlighting potential sex-specific therapeutic differences.

The authors conclude that integrating heart-in-a-dish technology with advanced single-cell biosensor microscopy successfully uncovers patient-specific molecular and functional phenotypes in DCM. While preliminary, this experimental pipeline provides a foundational pathway toward personalized medicine in heart failure. The research team is currently expanding this platform to an expanded cohort of 40 patients to further elucidate disease heterogeneity.

Link to the article: https://www.nature.com/articles/s44385-026-00111-8

References

Castagnola, G., Loggia, D., Bourque, K., Alim, K., Derish, I., Rody, E., Gryz, Z., Hawey, C., Jones-Tabah, J., Bhardwaj, A., Mouttet, L., Gendron, N., Giannetti, N., Cecere, R., Hui, S. K., & Hébert, T. E. (2026). Evaluating and comparing the signalling and functional landscape of hiPSC-CMs derived from patients with dilated cardiomyopathy. Npj Biomedical Innovations, 3(1), 55. https://doi.org/10.1038/s44385-026-00111-8